GlassScriptPhysician profile
Jason Nazar
NPI 1730521873
$4,108.81
in general payments reported to CMS, 2019-2025
40 companies · $957 in 2025
The $957 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $289 · 2021: $725 · 2022: $803 · 2023: $183 · 2024: $404 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.70 | 2021-2025 | |
| Pfizer INC. | $468.35 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $370.58 | 2021-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $205.99 | 2019-2022 | |
| Ucb, INC. | $201.19 | 2019-2022 | |
| Amgen INC. | $192.06 | 2019-2022 | |
| Ge Healthcare | $169.75 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $156.83 | 2019-2025 | Austedo Xr |
| Lilly USA, LLC | $138.32 | 2019-2025 | Amyvid, Kisunla |
| Celgene Corporation | $124.83 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $124.35 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $109.96 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $103.48 | 2020-2025 | Crexont, Rytary |
| Otsuka America Pharmaceutical, INC. | $103.13 | 2022-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $99.74 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Nazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.